Superworth

Protalix BioTherapeutics EV/EBIT PLX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Nov 2, 2026
7.5×
6-year median
14.8×
Against its 6-year history
24th
percentile: 0 is its lowest day, 100 its highest
6-year range
5.9× to 114×
Peer median
8.6×

Protalix BioTherapeutics' EV/EBIT is 7.5× as of Nov 2, 2026.

That is below its 6-year median of 14.8×, lower than on 76% of days in the last 6 years.

Over that time it ranged from 5.9× in May 2026 to 114× in Apr 2021.

The median for 10 healthcare stocks of a similar size is 8.6×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.5×5.9×35.3×
202519.5×10.9×52.3×
20246.7×6.2×8.4×
20238.5×6.1×9.7×
2022n/m a value too high to mean anything
202160.4×60.4×114×
202069.2×44.1×74.5×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

Where Protalix BioTherapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.